Commercial Opportunities for Western Europe and Middle East

NZX/ASX Announcement 19 December 2025 TruScreen investigates commercial opportunities for Western Europe and the Middle East • TruScreen’s India distributor, Renovate Biologicals Pvt Ltd has been authorised to investigate commercial opportunities in Western Europe and the Middle East • TruScreen to be launched for Europe and the Middle East at the upcoming World Health Expo in Dubai in February 2026 • Middle East countries have an estimated screening population of 99.7 million women* • Western European countries have an estimated screening population of 84.3 million women* TruScreen Group Limited (“TruScreen” or “the Company”) advises that it has authorised Renovate Biologicals Pvt Ltd (Renovate) to investigate commercial and market opportunities in the Middle East and Western Europe from 1 January 2026. Middle Eastern commercial activity has been authorised for Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, UAE, Lebanon, Iraq, Yemen, Iran and Turkey. These countries have an estimated screening population of 99.7 million women*. Renovate will represent Truscreen at the World Health Expo in Dubai from Feb 9 -12, 2026. Western European commercial activity has been authorised for Finland, United Kingdom, Netherlands, Belgium, Denmark, France, Sweden and Germany. These countries have an estimated screening population of 84.3 million women*. The TruScreen medical device is CE Mark (Conformité Européenne), certifying that it meets essential EU health, safety, and environmental standards and allowing it to be sold freely within the European Union. Renovate is a fast-growing international medical device distributor who was appointed, in April 2025, to distribute the TruScreen medical device in India. Established in 2015 in Hyderabad, Renovate distributes gold standard, advanced and innovative technologies which have transformed clinical outcomes in Diagnostics, Therapeutics, Critical Care, Organ Transplantation, Hematology and Ophthalmology to global markets. Renovate’s leadership team has a combined experience of over 50-man years and are supported by a rapidly expanding sales team and network of sub-distributors, with offices in Hyderabad, Singapore, Dubai and Amsterdam. The team aims to gain a 70-80% share of the cervical cancer screening device market by 2030. TruScreen CEO, Martin Dillon commented: “It is incredibly exciting to be launching TruScreen’s next phase of global marketing activity with Renovate. They are well positioned to support our continued global expansion, connecting us with government and screening initiative leaders. Western Europe has had a focus on cervical cancer for many years, and Middle Eastern countries have been increasing their efforts on women’s health. Significant barriers to full population screening remain and many of these countries are long way off meeting WHO target rates (70% by 2030), so the opportunity for TruScreen to have an impact on the incidence and mortality from cervical cancer in these regions is real.” This announcement has been approved by the Board. * CIA World Factbook (female population aged 15-64yrs) Ends For more information, visit www.truscreen.com or contact: Martin Dillon Chief Executive Officer martindillon@truscreen.com Guy Robertson Chief Financial Officer guyrobertson@truscreen.com